title: Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant.
abstract: OBJECTIVE
  The identification and quantification of potential drug-drug interactions is important for avoiding or minimizing the interaction-induced adverse events associated with specific drug combinations. Clinical studies in healthy subjects were performed to evaluate potential pharmacokinetic interactions between vortioxetine (Lu AA21004) and co-administered agents, including fluconazole (cytochrome P450 [CYP] 2C9, CYP2C19 and CYP3A inhibitor), ketoconazole (CYP3A and P-glycoprotein inhibitor), rifampicin (CYP inducer), bupropion (CYP2D6 inhibitor and CYP2B6 substrate), ethinyl estradiol/levonorgestrel (CYP3A substrates) and omeprazole (CYP2C19 substrate and inhibitor).
  
  
  METHODS
  The ratio of central values of the test treatment to the reference treatment for relevant parameters (e.g., area under the plasma concentration-time curve [AUC] and maximum plasma concentration [C max]) was used to assess pharmacokinetic interactions.
  
  
  RESULTS
  Co-administration of vortioxetine had no effect on the AUC or C max of ethinyl estradiol/levonorgestrel or 5'-hydroxyomeprazole, or the AUC of bupropion; the 90 % confidence intervals for these ratios of central values were within 80-125 %. Steady-state AUC and C max of vortioxetine increased when co-administered with bupropion (128 and 114 %, respectively), fluconazole (46 and 15 %, respectively) and ketoconazole (30 and 26 %, respectively), and decreased by 72 and 51 %, respectively, when vortioxetine was co-administered with rifampicin. Concomitant therapy was generally well tolerated; most adverse events were mild or moderate in intensity.
  
  
  CONCLUSIONS
  Dosage adjustment may be required when vortioxetine is co-administered with bupropion or rifampicin.
authors: Clinical Pharmacology, Takeda Development Center Americas, One Takeda Parkway, Deerfield, IL, 60015, USA, grace.chen@takeda.com.
authors: Grace
authors: G
authors: Chen
authors: Ronald
authors: R
authors: Lee
authors: Astrid-Maria
authors: AM
authors: Højer
authors: Jeppe Klint
authors: JK
authors: Buchbjerg
authors: Michael
authors: M
authors: Serenko
authors: Zhen
authors: Z
authors: Zhao
mesh_terms: D000293:Adolescent; D000328:Adult; D000928:Antidepressive Agents / Q000097:blood / Q000493:pharmacokinetics*; D000935:Antifungal Agents / Q000097:blood / Q000493:pharmacokinetics*; D016642:Bupropion / Q000097:blood / Q000493:pharmacokinetics; D015331:Cohort Studies; D003278:Contraceptives, Oral, Hormonal / Q000097:blood / Q000493:pharmacokinetics*; D018592:Cross-Over Studies; D004347:Drug Interactions / Q000502:physiology; D004790:Enzyme Induction / Q000187:drug effects / Q000502:physiology; D004791:Enzyme Inhibitors / Q000097:blood / Q000493:pharmacokinetics*; D005260:Female; D015725:Fluconazole / Q000097:blood / Q000493:pharmacokinetics; D006801:Humans; D007654:Ketoconazole / Q000097:blood / Q000493:pharmacokinetics; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000097:blood / Q000493:pharmacokinetics; D010879:Piperazines / Q000097:blood / Q000493:pharmacokinetics*; D012293:Rifampin / Q000097:blood / Q000493:pharmacokinetics; D016037:Single-Blind Method; D013440:Sulfides / Q000097:blood / Q000493:pharmacokinetics*; D000078784:Vortioxetine; D055815:Young Adult
chemical_list: D000928:Antidepressive Agents; D000935:Antifungal Agents; D003278:Contraceptives, Oral, Hormonal; D004791:Enzyme Inhibitors; D010879:Piperazines; D013440:Sulfides; D016642:Bupropion; D000078784:Vortioxetine; D015725:Fluconazole; D009853:Omeprazole; D007654:Ketoconazole; D012293:Rifampin
references: Clin Pharmacokinet. 1998 Nov;35(5):361-90
references: 9839089
references: Clin Pharmacokinet. 2005;44(3):279-304
references: 15762770
references: J Clin Psychiatry. 2012 Jul;73(7):953-9
references: 22901346
references: Basic Clin Pharmacol Toxicol. 2012 Sep;111(3):198-205
references: 22448783
references: Clin Pharmacokinet. 1995;29 Suppl 1:33-43; discussion 43-4
references: 8846621
references: Curr Med Res Opin. 2013 Mar;29(3):217-26
references: 23252878
references: Clin Pharmacokinet. 2003;42(2):153-78
references: 12537515
references: Pharmacology. 2010;86(4):203-15
references: 20829645
references: CNS Drugs. 2012 Jan 1;26(1):39-67
references: 22171584
references: Drug Metab Dispos. 2012 Jul;40(7):1357-65
references: 22496396
references: Clin Pharmacokinet. 2009;48(10):653-66
references: 19743887
references: J Med Chem. 2011 May 12;54(9):3206-21
references: 21486038
references: Int J Neuropsychopharmacol. 2013 Mar;16(2):313-21
references: 22963932
references: J Pharmacol Exp Ther. 2012 Mar;340(3):666-75
references: 22171087
references: Clin Pharmacokinet. 2006;45(10):1035-50
references: 16984215